Key Figures Q1 2021
|
SEK m, unless otherwise stated |
2021 Jan-Mar |
2020 Jan-Mar |
2020 Jan-Dec |
2020-2021 Jan-Mar Δ |
|
Net revenues |
132.3 |
175.0 |
663.6 |
-24% |
|
Cost of goods sold |
-19.2 |
-20.0 |
-65.6 |
-4% |
|
Operating expenses |
-149.9 |
-121.1 |
-617.9 |
24% |
|
EBIT |
-36.8 |
34.0 |
-19.9 |
-208% |
|
EBIT margin, % |
-27.8 |
19.4 |
-3.0 |
-47.2 ppt |
|
EBITDA |
23.9 |
39.1 |
19.0 |
-161% |
|
Earnings per share, before dilution, SEK |
-0.92 |
2.38 |
-2.45 |
-139% |
|
Earnings per share, after dilution, SEK |
-0.92 |
2.34 |
-2.45 |
-139% |
|
Cash flow from operating activities |
-47.8 |
48.1 |
16.8 |
-199% |
|
Cash and cash equivalents |
725.5 |
861.4 |
505.3 |
-16% |
Net revenues and EBIT per segment Q1 2021
|
SEK m |
Net Revenues |
EBIT |
||||
|
2021 Jan-Mar |
2020 Jan-Mar |
2020 Jan-Dec |
2021 Jan-Mar |
2020 Jan-Mar |
2020 Jan-Dec |
|
|
ZUBSOLV® US |
126.8 |
163.9 |
623.3 |
- |
- |
- |
|
US Pharma – total |
126.8 |
163.9 |
623.3 |
66.1 |
75.9 |
331.2 |
|
Digital Therapeutics (DTx) product sales |
0.2 |
- |
0.0 |
- |
- |
- |
|
Digital Therapeutics (DTx) – total |
0.2 |
- |
0.0 |
-58.7 |
-12.1 |
-175.4 |
|
Abstral® royalties |
2.7 |
8.6 |
29.7 |
- |
- |
- |
|
Edluar® royalties |
2.6 |
2.4 |
10.4 |
- |
- |
- |
|
ZUBSOLV® - ex US |
- |
0.1 |
0.1 |
- |
- |
- |
|
OX-MPI |
- |
- |
- |
- |
- |
- |
|
HQ & Pipeline segment – total |
5.3 |
11.1 |
40.2 |
-44.2 |
-29.9 |
-175.8 |
|
Total |
132.3 |
175.0 |
663.6 |
-36.8 |
34.0 |
-19.9 |
Cash flow Q1 2021
|
SEK m |
2021 Jan-Mar |
2020 Jan-Mar |
2020 Jan-Dec |
|
Cash flow from operating activities |
-47.8 |
48.1 |
16.8 |
|
Investment activities |
-16.2 |
-3.9 |
-189.2 |
|
Financing activities |
-261.7 |
-68.8 |
-111.3 |
|
Cash flow (excl exchange rate differences) |
197.7 |
-24.6 |
-283.7 |
|
Liquid funds |
725.5 |
861.4 |
505.3 |